GlobeNewsWire
22 Sept 2026, 12:47 UTC · 1h ago
Verdict
Headline takes no side. We score MAIA +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 94% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 2 new · 2 priced in
Ateganosine showed a 90.5% interim disease control rate (DCR) in heavily pretreated 3L NSCLC patients in the Phase 2 THIO-101 trial.
Newpress release dated Sept 22, 2026
So whatThis result is ~55% to 65% higher than the 25%–35% DCR associated with standard chemotherapy, significantly increasing the probability of Phase 3 success.
More positive than 99% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
MAIA has enrolled 65 patients in the pivotal Phase 3 THIO-104 trial and aims to exceed 100 randomized patients by year-end.
Newpress release dated Sept 22, 2026
So whatThe company needs to enroll 36+ more patients within the next 3 months to meet its goal.
More positive than 76% of claims this week
The FDA granted Fast Track designation for ateganosine in July 2025, making it eligible for Accelerated Approval and Priority Review.
Priced inevent occurred in July 2025
So whatPriority Review could shorten the FDA's goal for taking action on a complete application from 10 months to 6 months.
More positive than 61% of claims this week
If approved, ateganosine will receive FDA New Chemical Entity (NCE) five-year marketing exclusivity.
Priced indescription of NCE status
So whatFive-year exclusivity prevents generic competition until 2031 at the earliest, assuming approval within the next year.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
The company reported positive Phase 3 enrollment progress and high interim disease control rates for its lead cancer drug candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−0.8%
Price is moving against the score
$1.32 vs $1.33 close before publication (Sep 21) · not market-adjusted
MAIA chart →